Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.50 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.48 |
| ▸ | MMP2 | P08253 | 3/20 | 0.45 |
| ▸ | CA12 | O43570 | 2/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | MMP1 | P03956 | 1/20 | 0.45 |
| ▸ | MMP9 | P14780 | 1/20 | 0.45 |
| ▸ | MMP8 | P22894 | 1/20 | 0.45 |
| ▸ | MMP13 | P45452 | 1/20 | 0.45 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.43 |
| ▸ | F2 | P00734 | 2/20 | 0.41 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.41 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.41 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19518780 | 0.82 | TLR9 (0.50) | CA2PLCG1MMP2CA12CA9 | |
| SCHEMBL25428935 | 0.82 | TLR9 (0.50) | CA2PLCG1MMP2CA12CA9 | |
| SCHEMBL343050 | 0.78 | TLR9 (0.70) | CA2MMP2CA12CA9CA1 | |
| SCHEMBL15314697 | 0.78 | CA2 (0.52) | CA2PLCG1MMP2CA12CA9 | |
| SCHEMBL7150046 | 0.76 | LMNA (0.59) | CA2PLCG1MMP2CA12CA9 | |
| SCHEMBL29017279 | 0.76 | CA2 (0.50) | CA2PLCG1MMP2CA12CA9 | |
| SCHEMBL27649852 | 0.76 | ALDH1A1 (0.54) | CA2MMP2CA12CA9CA1 | |
| SCHEMBL9752512 | 0.76 | TSHR (0.54) | CA2MMP2CA12CA9CA1 | |
| SCHEMBL8488153 | 0.76 | CA2 (0.56) | CA2PLCG1MMP2CA12CA9 | |
| SCHEMBL214852 | 0.75 | TLR9 (0.58) | CA2MMP2CA12CA9CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080207706-A1 | THIADIAZOLINE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD (JP) | 2008-08-28 | — | — | US | claimed |
| US-20060074113-A1 | Thiadiazoline derivative | KYOWA KIRIN CO., LTD. (JP) | 2006-04-06 | — | — | US | claimed |
| EP-1454903-A1 | THIADIAZOLINE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2004-09-08 | — | — | EP | claimed |
| EP-1847534-B9 | Thiadiazoline derivatives for treating cancer | KYOWA HAKKO KIRIN CO LTD (JP) | 2012-03-21 | — | — | EP | disclosed |
| EP-1847534-B1 | Thiadiazoline derivatives for treating cancer | KYOWA HAKKO KIRIN CO LTD (JP) | 2011-06-22 | — | — | EP | disclosed |
| US-7902234-B2 | Thiadiazoline derivative | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2011-03-08 | — | — | US | disclosed |
| US-20100240716-A1 | THIADIAZOLINE DERIVATIVE | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-09-23 | — | — | US | disclosed |
| US-7759371-B2 | Thiadiazoline derivative | Kyowa Hakko Kinn Co., Ltd. (JP) | 2010-07-20 | — | — | US | disclosed |
| US-7425636-B2 | Thiadiazoline derivative | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2008-09-16 | — | — | US | disclosed |
| US-20080207706-A1 | THIADIAZOLINE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD (JP) | 2008-08-28 | — | — | US | disclosed |
| EP-1847534-A2 | Thiadiazoline derivative | Kyowa Hakko Kogyo Co., Ltd (JP) | 2007-10-24 | — | — | EP | disclosed |
| US-20070213380-A1 | Thiadiazoline derivative | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-09-13 | — | — | US | disclosed |
| US-20060074113-A1 | Thiadiazoline derivative | KYOWA KIRIN CO., LTD. (JP) | 2006-04-06 | — | — | US | disclosed |
| EP-1454903-A1 | THIADIAZOLINE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2004-09-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074113-A1 | Thiadiazoline derivative | BRWD1, RB1, ARG2 | CA2 4175/4885PLCG1 3368/4885MMP2 3801/4885 |
| US-20070213380-A1 | Thiadiazoline derivative | BRWD1, RB1, ARG2 | CA2 4175/4885PLCG1 3368/4885MMP2 3801/4885 |
| US-20100240716-A1 | THIADIAZOLINE DERIVATIVE | BRWD1, WDR82, RB1 | CA2 4059/4885PLCG1 3784/4885MMP2 3643/4885 |
| US-20080207706-A1 | THIADIAZOLINE DERIVATIVE | BRWD1, RB1, ARG2 | CA2 4175/4885PLCG1 3368/4885MMP2 3801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.